Is it safe to take Mobosetinib (Anvili) for a long time and what are the risks?

Mobocertinib is an oral EGFR exon 20 insertion mutation selective inhibitor, mainly used to treat patients with advanced or metastatic non-small cell lung cancer (NSCLC), especially for conventional EGFR Types of mutations that are resistant to targeted drugs. The drug can specifically inhibit the abnormal EGFR signaling pathway, thereby inhibiting tumor cell proliferation. Despite its remarkable efficacy, long-term use still requires attention to safety and potential risks.

Common adverse reactions of mobosetinib include Gastrointestinal reactions (such as diarrhea, nausea, vomiting), rash, stomatitis, and mild to moderate liver function abnormalities. These side effects can be alleviated in most patients through symptomatic treatment, dosage adjustment, or extending the dosing interval. However, long-term use without timely management may lead to weight loss, electrolyte imbalance, or decreased quality of life.

Mobosetinib may also affect liver and kidney function during long-term use . Clinical studies have shown that some patients experience elevated transaminases or serum creatinine. Therefore, patients need to regularly monitor liver and kidney function, blood routine and electrolyte levels during long-term medication in order to detect potential risks early and make dosage adjustments or take protective measures based on the monitoring results.

To ensure the safety of long-term medication, Individualized dose management and regular follow-up strategies should be adopted. Once moderate or above side effects or organ function abnormalities occur, the drug should be discontinued or the dosage should be reduced in time, and symptomatic treatment should be provided. Through standardized monitoring, reasonable dosage adjustment and lifestyle management, most patients can achieve long-term stable efficacy while controlling side effects, thereby obtaining sustained benefits in the treatment of advanced NSCLC.

Reference link:https://www.drugs.com